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http:WHAT THIS PAPER ADDS
Long-term results of subintimal angioplasty plus stent in a homogenous series of claudicants with femo-
ropopliteal occlusions.Objective: To assess a practice of claudicant revascularization with either subintimal angioplasty (SIA) plus
stenting or femoropopliteal bypass.
Methods: All claudicants related to femoropopliteal occlusions treated either with above-the-knee
femoropopliteal (AKFP) bypass (group 1) or SIA and stent (group 2) between 2004 and 2011 were reviewed. The
two groups were analyzed with regard to patency and freedom from re-intervention.
Results: One hundred and ﬁfty limbs were consecutively treated with AKFP bypass (n ¼ 82), SIA plus stenting
(n ¼ 58), or SIA (n ¼ 10). Bypasses were performed with synthetic grafts in 49 limbs (59.7%). Covered stents
were used in 34 limbs (63%) and self-expandable stents in the remainder. Mean follow-up was 26 and 36 months,
respectively, in group 1 and 2. At 24 months, primary, primary-assisted, and secondary patency for bypass versus
SIA þ stent groups was, respectively, 66.6 versus 70.1%, 76.5 versus 90.1%, and 88.2 versus 90.1%. Freedom from
re-intervention rates at 12 and 36 months were, respectively, 78.8 and 68.4% for group 2 and 86.4% and 65.2%
for group 1.
Conclusion: SIA plus stenting is an effective and useful option for the management of claudicants with
femoropopliteal occlusions, and can be considered as complementary to surgical bypass.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Over two decades, since the technique of subintimal an-
gioplasty (SIA) was ﬁrst described by Bolia et al.1 for the
treatment of long occlusive lesions, the indications remain
variable and controversial. Proponents of SIA use it as a
primary therapy for critical limb ischemia, as well as for
claudicants, whereas those who reject it use it solely for
candidates unsuitable for surgical bypass.2e5
Criticism of this technique has mainly concerned the
relatively low patency rates compared with surgical bypass.
These were evaluated to vary between 56 and 70% at 1
year6e8 independently of the degree of ischemia. In pa-
tients with critical limb ischemia, the relatively high re-
occlusion rates did not affect clinical outcomes as the
limb salvage rates reported in most series remained as high
as 80e90%.7 However, in claudicants, the clinical successrresponding author. M. Bouﬁ, Department of Vascular Surgery,
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//dx.doi.org/10.1016/j.ejvs.2013.06.003criterion is the relief of symptoms, which is directly related
to the patency. Thus, improvement of patency may allow
the widespread acceptance of this technique for
claudicants.
The loss of primary patency is probably multifactorial.
According to reports in the literature, a high rate of occlu-
sion occurs early during the ﬁrst 6 months.9 This suggests
that these occlusions can be related to elastic recoil with
residual stenosis and/or ﬂow-limiting spiral dissection. In
our practice femoropopliteal occlusions were managed
either with surgical bypass or subintimal recanalization,
depending principally on the lesion location. With a view to
improving patency, we often tended to combine SIA tech-
nique with stenting.
Our assumption is that the adjunction of stent to a
subintimal recanalization allows improvement of results and
optimization of the Bolia technique without competing with
the surgical bypass, which is considered as the standard
treatment.
To assess the place of SIA plus stenting in the treatment
of claudicants, we present an audit of our practice through
an analysis of patency and re-intervention rates in both an
endovascular group and a surgical group treated during the
same period.
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From February 2004 to February 2011, we retrospectively
reviewed all patients with disabling claudication admitted
to and treated in our department. Disabling claudication
was deﬁned as a measured walking distance of <100 m
with impairment of functional status and quality of life, and
an ankleebrachial index (ABI) < 0.5. All patients were
evaluated with computed tomography or magnetic reso-
nance angiography prior to the revascularization procedure.
Arterial occlusion only included femoropopliteal arteries.
Patients were treated either with above-the-knee femo-
ropopliteal bypass, SIA, or SIA plus stenting. Data including
patient demographics, associated co-morbidities, anatom-
ical features of lesions, Society of Vascular Surgery runoff
score,10 operative reports, and outcomes were reviewed.Indications
Depending on the extent of the occlusion into the femo-
ropopliteal segment and the re-entry site, we arbitrarily
divided the lesion level into middle or distal superﬁcial
femoral artery (SFA), proximal SFA occlusion, total SFA, or
femoropopliteal occlusion.
The choice of revascularization technique depended on
the surgeon’s preference and the extent of the lesions.
Middle or distal SFA occlusions are considered favorable
anatomy and, consequently, only the endovascular proce-
dure was attempted. In contrast, for the technically more
complex proximal, total SFA, or femoropopliteal occlusions,
the decision to undertake one or the other technique was
left to the surgeon’s discretion.
After SIA procedures, the indication for stenting depen-
ded on the location and lesion length, and the angiogram
results after angioplasty. Stents were indicated for long
occlusions (10 cm) and/or blood ﬂow limitation related to
intimal ﬂap or residual atherosclerotic stenosis >30%.
Stents were not used for recanalization with a re-entry zone
below the knee joint or for short occlusions with no blood
ﬂow limitation on angiogram.Techniques
Femoropopliteal bypass was performed with the usual
technique. The conduits used were either synthetic or
saphenous vein grafts. Graft diameters varied from 6 to
8 mm depending on the diameter of popliteal artery eval-
uated preoperatively. Our policy is generally to use pros-
thesis in elderly patients or in cases of co-morbidities, in
those with unsuitable vein (diameter < 5 mm), and those
with a good run off vessel; however, the ﬁnal decision was
left to the surgeon’s discretion. Post-operatively, patients
were placed on a single antiplatelet therapy.
All endovascular procedures were performed in the
operating theater under general anesthesia, or local anes-
thesia with conscious sedation. The ipsilateral common
femoral artery was the preferred angiographic access. A
controlateral femoral artery puncture was used in cases of
ﬂush SFA occlusion, previous groin surgery, or obesepatients. More recently, ﬂush occlusion treatment with
above-the-knee re-entry was attempted via an up and over
approach through popliteal ponction.
All patients with signiﬁcant stenosis of the ipsilateral iliac
or common femoral artery were treated during the same
procedure in order to improve the inﬂow.
For those with signiﬁcant stenosis of the common
femoral artery or the profunda femoris artery, a surgical
approach with a femoral bifurcation endarterectomy or
femoro-femoral bypass was performed ﬁrst, after which the
patch graft used for the closure of the arteriotomy was
punctured and the endovascular procedure was completed.
After artery puncture, an angiography was performed via
a 5F sheath to identify the arterial occlusion, plan for the re-
entry zone, and deﬁne the run-off vessels. A 5 F straight
angiography catheter (Glidecath, Terumo Medical Corpora-
tion, Somerset, NJ, USA) was generally used to enter the
subintimal space in combination with the guidewire tip. The
occlusion was then crossed with a looped guidewire fol-
lowed by a straight catheter. The re-entry into the true
lumen was obtained either by means of catheter guidewire
manipulations or by pushing the looped guidewire toward
the patent vessel at the end of the occlusion site. Re-entry
devices were not used in these patients because they were
not available in our department during the study period.
The subintimal space was then dilated.
Unlike the Bolia technique,1 we believe that adjunction of
stent along the entire length of the recanalized artery and
not only at the entry or re-entry site can improve patency
rates. Consequently, we adopted a liberal approach to
stenting, except when the re-entry into the true lumen is
performed at the level of the knee joint or for short oc-
clusion with no blood ﬂow limitation on angiogram.
Either self-expandable stents or covered stents were used
in these patients. At the beginning of our experience,
covered stents were the sole stents used. Currently, self-
expandable stents are preferreddin particular, for long
occlusion and/or when there are large collaterals in the
treated segment which risk being covered. Combined pro-
cedures included all endovascular or surgical procedures
used during the femoropopliteal recanalization in order to
improve inﬂow.
During the procedure, all patients received 50 IU per kg
of heparin intravenously, and for those who were not
impregnated with antiplatelet agents, 250 mg aspirin was
systematically added intravenously. After a successful pro-
cedure, patients received aspirin and clopidogrel for 6
months followed indeﬁnitely by either aspirin or clopidog-
rel. Patients receiving Warfarin therapy were continued on
the drug associated with aspirin.Follow-up
Systematic follow-up included a clinical examination and
duplex ultrasound scanning at 1, 3, 6, and 12 months, and
thereafter yearly for the endovascular group, and at 1, 6,
and 12 months and thereafter yearly for the surgical group.
Patency was assessed by means of palpable pedal pulse,
Table 1. Demographic data, risk factors for atherosclerosis and
anatomical features of lesions.
Group 1(%)
(bypass, n ¼ 82)
Group 2(%)
(Bolia þ stent,
n ¼ 58)
Age (years)
Mean  SD 64.7  10.7 67.7  10.3
Range 38e82 40e88
Male gender 54.0 (65.8) 41.0 (67.2)
Risk factors
Diabetes mellitus 39.0 (49.3) 27.0 (47.3)
History of smoking 46.0 (58.2) 37.0 (64.9)
Hypertension 23.0 (29.0) 15.0 (26.3)
hyperlipidemia 11.0 (13.9) 6.0 (10.5)
Renal insufﬁciency 5.0 (6.3) 6.0 (10.5)
Rutherford classiﬁcation
II 35.0 (42.6) 27.0 (46.5)
III 47.0 (57.3) 31.0 (53.4)
TASC classiﬁcation
A 0.0 2.0 (3.4)
B 8.0 (9.7) 9.0 (15.5)
C 36.0 (43.9) 19.0 (32.7)
D 38.0 (46.3) 28.0 (48.2)
Run-off score
1.0e3.0 26.0 (31.7) 21.0 (36.2)
3.5e5.0 28.0 (34.1) 23.0 (39.6)
5.5e7.0 17.0 (20.7) 7.0 (12.0)
7.5e10.0 11.0 (13.4) 7.0 (12.0)
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between the peak systolic velocities of the segment treated
and the proximal artery. Restenosis was deﬁned as signiﬁ-
cant recurrent stenosis of more than 50% and/or a velocity
ratio between the common femoral artery and popliteal
artery of more than 3.
A computed tomography angiography scan was obtained
for recurrent claudication with restenosis or thrombosis on
the basis of the duplex scan.
All additional endovascular or surgical procedures to
maintain or restore patency, as well as all amputations and
deaths, were recorded until November 2011.
Freedom from re-intervention rates are arbitrary data
used as a quality of life criteria, and included not only re-
interventions performed for restenosis or thrombosis but
also hematoma, bleeding, infection, or amputation.
The primary endpoints of the study were the primary,
primary-assisted, and secondary patency, and the secondary
endpoint was the freedom from re-intervention rate.
Continuous variables were expressed as mean  SD,
whereas categorical data was presented in the form of
frequencies and percentages. Patency and freedom from re-
intervention rates were analyzed on an intention-to-treat
basis and were calculated using KaplaneMeier survival
analysis. This analysis was performed using the IBM SPSS
statics v.17.0 software package (SPSS, Chicago, IL, USA).Note. TASC ¼ TransAtlantic InterSociety.RESULTS
Over the study period, a total of 150 limbs (146 patients)
were consecutively treated for disabling claudication
(Rutherford grades 2 or 3)10 related to femoropopliteal
occlusions with femoropopliteal bypass (n ¼ 82; group 1),
SIA plus stenting (n ¼ 58; group 2), or SIA (n ¼ 10). Owing
to the low rate of limbs treated with simple SIA, only the
SIA plus stenting group and the femoropopliteal bypass
group were considered.
All patients had previously been submitted to at least 3
months of appropriate medical treatment, including smok-
ing cessation, unsupervised physical activity, control of
atherosclerotic risk factors, and optimal drugs therapy.
Mean age was 66 years (range, 40e88 years) and 65%
(n ¼ 95) were men. Our cohort had the usual associated co-
morbidities; 45.2% were diabetic. The demographic data for
each group are presented in Table 1.
In the endovascular group, the procedure was technically
successful in 93% of limbs (n ¼ 54). Failure (n ¼ 4) occurred
in patients with TransAtlantic InterSociety D (n ¼ 3) or C
(n ¼ 1) lesions, and was attributed in three patients to the
inability to re-enter the true lumen because of heavy cal-
ciﬁcations, and in one to the impossibility of entering the
subintimal space owing to the presence of a tight SFA
stenosis upstream of the occlusion. Three of the four pa-
tients who experienced a technical failure had an above-
the-knee femoropopliteal bypass, and the fourth patient
declined further intervention.
Adjunctive procedures were required in the treatment of
29.6% of limbs (n ¼ 16) to improve the inﬂow. Theseincluded open common femoral endarterectomy (n ¼ 8)
and iliac angioplasty with stenting (n ¼ 8). The Viabahn
(W.L. Gore & Associates, Flagstaff, AZ, USA) stent-graft was
used in 34 limbs (63%) and self-expandable nitinol Lifestent
stents (C.R. Bard, Murray Hill, NJ, USA) in the remainder. The
mean length of the arterial occlusion was 16 cm (range, 4e
40 cm), and the mean number of stents or stentegrafts
deployed in the recanalized artery was 1.5 (range, 1e
3).There were three major post-procedural complications
(5.5%): one groin infection following femoral endarterec-
tomy plus SIA, treated with surgical revision and antibiotic
therapy; one groin hematoma; and one acute limb ischemia
related to acute thrombosis of the femoropopliteal segment
that needed an above-the-knee femoropopliteal bypass.
In the surgical group, femoropopliteal above-the- knee
bypass was successfully performed in 100% of the limbs
treated. Synthetic grafts (polytetraﬂuoroethylene) were
used in 49 limbs (59.7%) and saphenous vein in 33 limbs
(40.2%). The early post-operative complications occurred in
16 of 82 limbs (19.5%): seven immediate thrombosis were
treated with thrombectomy and refection of anastomosis
(n ¼ 5) or replacement of the synthetic graft by saphenous
vein (n ¼ 2); one instance of signiﬁcant bleeding required
surgical exploration; six wound complications were resolved
without intervention; and two instances of myocardial
ischemia were treated medically.
There was no peri-operative (30 days) death or limb loss
in either of the groups.
The mean follow-up was 36 months (range, 1e94
months) in group 2 and 26 months (range, 2e84 months) in
Table 2. Primary, primary-assisted, and secondary patency rates of
subintimal angioplasty plus stent group, all bypasses group, and
individual prosthesis and vein bypasses groups.
Patency 30-day 1 year 2 years 3 years
SIA þ stenting
Primary 96.6 76.9 70.1 64.6
Primary-assisted 96.6 90.1 90.1 90.1
Secondary 96.6 90.1 90.1 90.1
All bypasses
Primary 90.2 79.5 66.6 58.5
Primary-assisted 90.2 83.6 76.5 68.6
Secondary 97.5 90.6 88.2 84.0
Prosthesis bypasses
Primary 89.9 77.9 63.0 47.2
Primary-assisted 89.9 81.3 72.3 56.2
Secondary 97.9 92.5 87.8 78.1
Vein bypasses
Primary 90.6 82.0 71.8 71.8
Primary-assisted 90.6 86.8 81.7 81.7
Secondary 96.9 88.5 88.5 88.5
Note. SIA ¼ subintimal angioplasty.
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and for 95% of patients in group 1. Four patients were lost
to follow-up. The mean increase in ABI in successfully
treated patients was 0.38  0.2 in the group 2 and
0.48  0.16 in group 1. The primary patency rates at 12, 24,
and 36 months were, respectively, 76.9% (SE, 5.9%), 70.1%
(SE, 6.5%), and 64.6% (SE, 7.1) for group 2, and 79.5% (SE,
5.1%), 66.6% (SE, 6.9%), and 58.5% (SE, 8.1%) for group 1
(Table 2). During the follow-up period, in group 2, nine
arteries re-occluded and ﬁve others restenosed. All throm-
bosis and three restenosis occurred in patients with Via-
bahn stentegraft. Secondary intervention was performed in
seven of the limbs treated for thrombosis (13%) with
recurrent claudication and included above-the-knee femo-
ropopliteal bypass in six and thrombectomy plus angio-
plasty in one. Two patients were successfully treated
medically for asymptomatic thrombosis, thus needing no
further intervention. In order to maintain patency, addi-
tional endovascular procedures for signiﬁcant restenosis
consisted of two angioplasties and three angioplasties plus
stenting.
In the surgical group, 11 thrombosis (synthetic grafts
n ¼ 7 and venous grafts n ¼ 4) and two restenosis occurred
during follow-up. All restenosis were successfully treated
with angioplasty and stent. Six of the 11 thrombosed by-
passes were treated with either below-the- knee-popliteal
bypass (n ¼ 4) or thrombectomy with surgical revision of
the distal anastomosis (n ¼ 2). No repeat intervention was
performed in the other ﬁve limbs because they had only
mild claudication. At 12, 24, and 36 months, this achieved
primary-assisted patency rates of, respectively, 90.1% (SE,
4.2%), 90.1% (SE, 4.2%), and 90.1% (SE, 4.2%) in group 2,
and 83.6% (SE, 4.4%), 76.5% (SE, 5.6%), and 68.6% (SE,
7.3%) in group 1 (Table 2). Secondary patency after 12 and
36 months was 90.1% (SE,4.2%) and 90.1% (SE, 4.2%) for
group 2 and 90.6% (SE, 3.8%) and 84% (SE, 5.8%) for group
1 (Table 2).During the study, no amputations were performed and
six patients died (11%) in the endovascular group, with
patent subintimal recanalization based on data from the last
clinical examination and/or duplex ultrasound imaging. In
group 1, two major amputations were necessary and eight
patients died (10.2%) with patent bypass in four and after
amputation in the other two. Overall, secondary interven-
tion was performed in 14 limbs (24%) in group 2 and in 17
limbs (20.7%) in group 1. This achieved freedom from re-
intervention rates at 12 and 36 months of, respectively,
78.8% and 68.4% for group 2, and 86.4% and 65.2% for
group 1 (Fig. 1).DISCUSSION
As recommended, our approach is to restrict revasculariza-
tion to patients with disabling claudication for whom the best
medical therapy and exercise advice have been ineffective.
In our practice, either surgical bypass or endovascular
recanalization are available and are used as the primary
revascularization options for these patients. The proportion
of claudicants with femoropopliteal occlusions treated with
SIA was 39%. The rationale behind this choice is that, ﬁrst,
SIA offers the least invasive technique, making it possible to
preserve the saphenous vein and avoid or defer the need for
surgical bypass. Second, technical failure and re-occlusion do
not preclude a successful femoropopliteal bypass.
The distal and middle SFA occlusions are considered
favorable anatomy for SIA because of the presence of a
good starting stump, making it possible to create the
dissection plane, and also the presence of a portion of the
SFA upstream of the knee joint for the re-entry zone. These
lesions are treated in prime intention with SIA. However, for
ﬂush SFA occlusions, total SFA, and femoropopliteal occlu-
sions, which are technically more complex, the decision is
left to the surgeon’s discretion. Rather than replace surgical
bypass with an endovascular technique, our attitude aimed
to add SIA to the armamentarium of vascular surgeons for
optimal management of claudicants.
Relatively few studies including solely claudicants treated
with SIA have been published.4,11,12 None of these studies
has presented concomitant results of surgery and SIA.
Moreover, the role of stent deployment after SIA remains
unclear,13e16 and no reports have evaluated the results in
claudicant patients.
Flørenes et al.4 in a series of 104 patients treated with
SIA used only primary-assisted patency to evaluate the re-
sults. Furthermore, they made no distinction in terms of
lesion location between femoropopliteal and tibial lesions.
Berengoltz-Zlochin et al.12 in a comparative study of sub-
intimal (n ¼ 20) versus intraluminal laser-assisted recana-
lization (n ¼ 42) reported an angiographic cumulative
primary patency rate of 93% at 1 year and a cumulative
restenosis/re-occlusion-free patency rate of 63% also at 1
year. London et al.11 presented a series of SIA on 200
femoropopliteal occlusions with hemodynamic patency at
12 and 36 months of 71% and 58%, respectively. In contrast
to what has so far been reported, our study includes a
Figure 1. Actuarial freedom from re-intervention of bypass (group 1) versus subintimal angioplasty plus stent group (group 2).
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sible for disabling claudication and gives mid-term primary,
primary-assisted, and secondary patency rates. The primary-
assisted patency rates in our series were better than those
reported by Flørenes et al.4 (94.3% vs. 62% at 12 months
and 89.9% vs. 57% at 36 months). This can be explained by
the stent adjunction. Our results cannot be compared with
those of London et al.11 because the deﬁnition of patency
used in their series was based only on the analysis of ABI
modiﬁcation during the follow-up and not on duplex ul-
trasound imaging.
In our experience outcome data showed comparable
results between the endovascular and surgical groups,
except for the primary-assisted patency, which was higher in
the endovascular group probably owing to a more rigorous
follow-up.
Even though the advantages of stents with correction of
residual stenosis, treatment of elastic recoil, and exclusion
from circulation of the potentially thrombogenic subintimal
channel are well recognized, data regarding the role of
routine stents in improving patency after subintimal
revascularization are more mitigated.13e16 Schmieder
et al.,13 in a comparative study between two groups with
and without stent, including claudicants and critical limb
ischemia, showed that a selective stent placed after SIA
resulted in a similar patency to primary SIA without stents.
Two other studies14,15 have assessed the effect of pri-
mary stenting on patency after SIA in mixed groups of le-
sions and degrees of ischemia, and have shown a relatively
favorable outcome in the short and intermediate term.
One of the advantages of SIA is the maintenance, and
possible opening, of new collaterals that explain the
possible asymptomatic re-occlusion during the follow-up.
Opponents of stent placement following SIA point, on theone hand, to the loss of these collaterals by deploying stent
in the subintimal channel and, on the other, the risk of stent
thrombosis interfering with the surgical bypass in the pa-
tients who ultimately required it. In our study, none of the
stent failures required emergency intervention, and all
symptomatic re-occlusions were treated either with above-
the knee femoropopliteal bypass or thrombectomy.
In our previous article,16 which compared covered stents
placed across the entire length of the recanalized artery
with no stent in a population study including claudicants
and critical limb ischemia, we failed to ﬁnd a difference in
terms of primary, primary-assisted, or secondary patency.
What differs with the present study is that all the patients
were claudicants and the stents used included stentegrafts
and bare metal stents.
One of the limitations of SIA is the risk of re-intervention
secondary to restenosis or rethrombosis, which worsen the
clinical outcome. Schmieder et al.,17 in a series of claudicants
and critical limb ischemia with femoropopliteal occlusions,
reported a 25% re-intervention rate occurring earlydon
average, 7.8 months after the initial intervention. This rate is
similar to what has been reported for surgical bypass, as
15e20% of patients required revision, except that the mean
time of these re-interventions was at 12e15 months.18e20
In our study freedom from re-intervention data showed
similar re-intervention rates between the surgical group and
the SIA plus stenting group occurring during the ﬁrst 24
months. This suggests a need for a close and continuous
surveillance protocol for recanalization, just as for bypasses.
Most of the studies published recently have tried to
demonstrate the effectiveness of recanalization techniques
in the treatment of infrainguinal lesions with a view to
ﬁnding an alternative to traditional surgical bypass. Our
assumption, conﬁrmed in the present study, that the
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lesions, and surgery for more complex lesions provides
good results. Thus, the two techniques are available and can
be used as complementary options for the treatment of
these patients.
We fully recognize the limitations of the present study,
which can be attributed to the following factors. First, to the
retrospective design of the study. Second, to the patient se-
lection criteria for one technique or the other, which
depended partially on the surgeon’s preferences and not only
on the lesion location. Finally, freedom from re-intervention
data was used to provide information on quality of life.
However, the effect was not assessed by a quality of life score.
The results should therefore be interpreted with caution.
CONCLUSION
Our study provides additional evidence that endovascular
treatment with SIA plus stenting has an important role to
play in the management of claudicants with long femo-
ropopliteal occlusions. The role of stent adjunction to Bolia’s
standard technique needs to be clariﬁed with a comparative
study between SIA and SIA plus stenting.
The indication for surgical or endovascular technique can
be dictated by the anatomy of occlusion. Rather than
competing with each other, we are convinced that the two
techniques, surgical bypass and SIA plus stenting, are
complementary.
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